JP2001507677A - 呼吸器疾患および肺の炎症に関連する疾患および状態のための薬剤ならびに治療法 - Google Patents

呼吸器疾患および肺の炎症に関連する疾患および状態のための薬剤ならびに治療法

Info

Publication number
JP2001507677A
JP2001507677A JP52489698A JP52489698A JP2001507677A JP 2001507677 A JP2001507677 A JP 2001507677A JP 52489698 A JP52489698 A JP 52489698A JP 52489698 A JP52489698 A JP 52489698A JP 2001507677 A JP2001507677 A JP 2001507677A
Authority
JP
Japan
Prior art keywords
drug
receptor
adenosine
antisense
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP52489698A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001507677A5 (enExample
Inventor
ナイス，ジョナサン，ダブリュー
Original Assignee
イースト・カロライナ・ユニバーシティー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イースト・カロライナ・ユニバーシティー filed Critical イースト・カロライナ・ユニバーシティー
Publication of JP2001507677A publication Critical patent/JP2001507677A/ja
Publication of JP2001507677A5 publication Critical patent/JP2001507677A5/ja
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP52489698A 1996-11-26 1997-11-26 呼吸器疾患および肺の炎症に関連する疾患および状態のための薬剤ならびに治療法 Ceased JP2001507677A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/757,024 US6025339A (en) 1995-06-07 1996-11-26 Composition, kit and method for treatment of disorders associated with bronchoconstriction and lung inflammation
US08/757,024 1996-11-26
PCT/US1997/022017 WO1998023294A1 (en) 1996-11-26 1997-11-26 Agent and method of treatment for diseases and conditions associated with respiratory ailments and lung inflammation

Publications (2)

Publication Number Publication Date
JP2001507677A true JP2001507677A (ja) 2001-06-12
JP2001507677A5 JP2001507677A5 (enExample) 2004-11-25

Family

ID=25046042

Family Applications (1)

Application Number Title Priority Date Filing Date
JP52489698A Ceased JP2001507677A (ja) 1996-11-26 1997-11-26 呼吸器疾患および肺の炎症に関連する疾患および状態のための薬剤ならびに治療法

Country Status (7)

Country Link
US (1) US6025339A (enExample)
EP (1) EP0946201A4 (enExample)
JP (1) JP2001507677A (enExample)
CN (1) CN1247473A (enExample)
AU (1) AU5368898A (enExample)
CA (1) CA2272900A1 (enExample)
WO (1) WO1998023294A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6239116B1 (en) * 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US7935675B1 (en) * 1994-07-15 2011-05-03 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US7034007B1 (en) 1995-06-07 2006-04-25 East Carolina University Low adenosine anti-sense oligonucleotide, compositions, kit & method for treatment of airway disorders associated with bronchoconstriction, lung inflammation, allergy(ies) & surfactant depletion
US6825174B2 (en) 1995-06-07 2004-11-30 East Carolina University Composition, formulations & method for prevention & treatment of diseases and conditions associated with bronchoconstriction, allergy(ies) & inflammation
KR20010030622A (ko) * 1997-09-17 2001-04-16 리차드 알. 이킨 다중 표적 하이브리드형성 핵산과 그들의 제조, 구성,제제, 키트 및 응용
US20040186071A1 (en) * 1998-04-13 2004-09-23 Bennett C. Frank Antisense modulation of CD40 expression
JP2002514397A (ja) * 1998-05-14 2002-05-21 コーリー ファーマシューティカル ゲーエムベーハー ＣｐＧオリゴヌクレオチドを用いる造血調節の方法
AU4675699A (en) * 1998-06-08 1999-12-30 Epigenesis Pharmaceuticals, Inc. Composition and method for prevention and treatment of cardiopulmonary and renal failure or damage associated with ischemia, endotoxin release, ards or brought about by administration of certain drugs
US6344475B1 (en) * 1998-10-27 2002-02-05 Yale University Conductance of improperly folded proteins through the secretory pathway
US6211162B1 (en) * 1998-12-30 2001-04-03 Oligos Etc. Inc. Pulmonary delivery of protonated/acidified nucleic acids
US7868162B2 (en) 1998-12-30 2011-01-11 Lakewood-Amedex, Inc. Antimicrobial and antiviral compounds and methods for their use
US6627215B1 (en) 1998-12-30 2003-09-30 Oligos Etc. Inc. Devices for improved wound management
CN1330513A (zh) * 1999-04-06 2002-01-09 东卡罗来纳大学 低腺苷反义寡核苷酸、组合物、试剂盒及与支气管紧缩、肺炎、过敏及表面活性剂缺失相关的通气途径疾病的治疗方法
US7585847B2 (en) * 2000-02-03 2009-09-08 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for the treatment of asthma and allergy
WO2002081628A2 (en) * 2001-04-05 2002-10-17 Ribozyme Pharmaceuticals, Incorporated Modulation of gene expression associated with inflammation proliferation and neurite outgrowth, using nucleic acid based technologies
AU2003300919A1 (en) * 2002-12-11 2004-06-30 Coley Pharmaceutical Gmbh 5' cpg nucleic acids and methods of use
AU2004226605A1 (en) * 2003-04-02 2004-10-14 Coley Pharmaceutical Group, Ltd. Immunostimulatory nucleic acid oil-in-water formulations for topical application
JP2007506440A (ja) 2003-09-29 2007-03-22 トピジェン・ファルマスーティック・インコーポレーテッド 炎症性症状を含む疾患を治療するための、オリゴヌクレオチド組成物および方法
TWI235440B (en) * 2004-03-31 2005-07-01 Advanced Semiconductor Eng Method for making leadless semiconductor package
US8119790B2 (en) 2004-10-29 2012-02-21 Topigen Pharmaceuticals Inc. Antisense oligonucleotides for treating allergy and neoplastic cell proliferation
CN101193646A (zh) * 2005-04-08 2008-06-04 科勒制药集团公司 治疗传染病加剧性哮喘的方法
US7982028B2 (en) * 2006-05-19 2011-07-19 Topigen Pharmaceuticals, Inc. Oligonucleotides affecting expression of phosphodiesterases
US8916531B2 (en) * 2007-11-20 2014-12-23 Isis Pharmaceuticals, Inc. Modulation of CD40 expression
US8202848B2 (en) * 2008-03-17 2012-06-19 Board Of Regents, The University Of Texas System Identification of micro-RNAS involved in neuromuscular synapse maintenance and regeneration
JP2011519579A (ja) 2008-05-15 2011-07-14 トピジェン ファーマスーティカルズ インク 炎症および新生細胞増殖の治療のためのオリゴヌクレオチド
US11401303B2 (en) * 2020-06-15 2022-08-02 Taian City Qihang Biotechnology Co. Synthetic peptide BRAP and application in preparation of anti-inflammatory drug for COVID-19 thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225326A (en) * 1988-08-31 1993-07-06 Research Development Foundation One step in situ hybridization assay
US5245022A (en) * 1990-08-03 1993-09-14 Sterling Drug, Inc. Exonuclease resistant terminally substituted oligonucleotides
US5858784A (en) * 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
GB2264948B (en) * 1992-03-13 1996-10-16 Merck & Co Inc Human adenosine receptors
WO1993025677A1 (en) * 1992-06-12 1993-12-23 Garvan Institute Of Medical Research DNA SEQUENCES ENCODING THE HUMAN A1, A2a and A2b ADENOSINE RECEPTORS
US5320962A (en) * 1992-07-22 1994-06-14 Duke University DNA encoding the human A1 adenosine receptor
US5585479A (en) * 1992-07-24 1996-12-17 The United States Of America As Represented By The Secretary Of The Navy Antisense oligonucleotides directed against human ELAM-I RNA
US5994315A (en) * 1995-06-07 1999-11-30 East Carolina University Low adenosine agent, composition, kit and method for treatment of airway disease
US6040296A (en) * 1995-06-07 2000-03-21 East Carolina University Specific antisense oligonucleotide composition & method for treatment of disorders associated with bronchoconstriction and lung inflammation

Also Published As

Publication number Publication date
EP0946201A4 (en) 2002-06-12
EP0946201A1 (en) 1999-10-06
CA2272900A1 (en) 1998-06-04
CN1247473A (zh) 2000-03-15
US6025339A (en) 2000-02-15
AU5368898A (en) 1998-06-22
WO1998023294A1 (en) 1998-06-04

Similar Documents

Publication Publication Date Title
JP2001507677A (ja) 呼吸器疾患および肺の炎症に関連する疾患および状態のための薬剤ならびに治療法
US6040296A (en) Specific antisense oligonucleotide composition & method for treatment of disorders associated with bronchoconstriction and lung inflammation
US5994315A (en) Low adenosine agent, composition, kit and method for treatment of airway disease
WO1998023294A9 (en) Agent and method of treatment for diseases and conditions associated with respiratory ailments and lung inflammation
JP2003517428A (ja) 複数標的ハイブリダイゼーション用核酸、その調製、組成物、製剤、キット及び応用
JP2015518710A (ja) ヘモグロビン遺伝子ファミリー発現を調節するための組成物及び方法
JP2015007065A (ja) 粘液分泌を変化させる方法および組成物
US6825174B2 (en) Composition, formulations & method for prevention & treatment of diseases and conditions associated with bronchoconstriction, allergy(ies) & inflammation
AU758447B2 (en) Antisense oligonucleotides for treating or preventing atopic diseases and neoplastic cell proliferation
CA2976576A1 (en) Compositions and methods for modulating rna
WO2000051621A1 (en) Method for validating/invalidating target(s) and pathways
AU724817B2 (en) Method of treatment for asthma
AU699330C (en) Method of treatment for asthma
US20050014711A1 (en) Composition, formulations & methods for prevention and treatment of diseases and conditions associated with bronchoconstriction, allergy(ies) and inflammation
AU753972B2 (en) Low adenosine oligonucleotide, composition, kit and methods for obtaining oligonucleotide and for treatment of airway disease(s)
US20110196018A1 (en) Nuclease resistant external guide sequences for treating inflammatory and viral related respiratory diseases
HK1023952A (en) Agent and method of treatment for diseases and conditions associated with respiratory ailments and lung inflammation
MXPA97009865A (en) Method of treatment for a
HK1016469A (en) Method of treatment for asthma
MXPA00004001A (es) Composicion y metodo para la prevencion y tratamiento de insuficiencia o dano cardiopulmonar y renal asociado con isquemia, liberacion de endotoxinas, sindrome de esfuerzo respiratorio agudo o provocado por la administracion de ciertos farmacos.

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20031201

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20031201

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20070619

A313 Final decision of rejection without a dissenting response from the applicant

Free format text: JAPANESE INTERMEDIATE CODE: A313

Effective date: 20071107

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20071218